EVOGENE LTD. (EVGN) — 分析摘要
EVOGENE LTD.（EVGN）的市值为5.62百万美元，最近一年的营收同比增长了-54.7%。净利润率为-203.1%。当前市盈率为-0.7倍。
核心要点
- 营收同比变化-54.7%
- 净利润率-203.1%
- 市盈率-0.7倍
EVGN的营收增长为-54.7%，市盈率为-0.7倍。
EVOGENE LTD. (EVGN)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -7.3x — 盈利不足以覆盖利息支出
营业利润率为 -364.2% — 严重经营亏损
净利率为 -203.1% — 亏损超过收入（可能含一次性费用）
毛利率为负 (-6.3%) — 低于成本销售
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
员工人数
52
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。